Key result
Clinical risk scores showed modest predictive ability for 5-year all-cause mortality in atrial fibrillation, with c-indexes of 0.64 for CHADS2 and 0.62 for CHA2DS2-VASc.
Why the study?
Many clinical risk stratification scores have been proposed for atrial fibrillation patients, and this study aimed to analyze the relationship between clinical risk scores and all-cause death.
Do clinical risk scores predict all-cause mortality in patients with atrial fibrillation?
Systematic Review (n=669,217)
Do clinical risk scores predict all-cause mortality in patients with atrial fibrillation?
Effect estimate: c-index 0.64 (CHADS2) (95% CI 0.63-0.65)
Contemporary clinical risk scores, particularly CHA2DS2-VASc, are associated with an increased risk of all-cause death in atrial fibrillation patients and can be used as part of holistic clinical assessment.
AF risk scores associate with higher all-cause mortality; leaves open their incremental value for holistic management.
Aims Many clinical scores for risk stratification in patients with atrial fibrillation have been proposed, and some have been useful in predicting all-cause mortality. We aim to analyse the relationship between clinical risk score and all-cause death occurrence in atrial fibrillation patients. Methods We performed a systematic search in PubMed and Scopus from inception to 22 July 2017. We considered the following scores: ATRIA-Stroke, ATRIA-Bleeding, CHADS 2 , CHA 2 DS 2 -VASc, HAS-BLED, HATCH and ORBIT. Papers reporting data about scores and all-cause death rates were considered. Results Fifty studies and 71 scores groups were included in the analysis, with 669,217 patients. Data on ATRIA-Bleeding, CHADS 2 , CHA 2 DS 2 -VASc and HAS-BLED were available. All the scores were significantly associated with an increased risk for all-cause death. All the scores showed modest predictive ability at five years (c-indexes (95% confidence interval) CHADS 2 : 0.64 (0.63–0.65), CHA 2 DS 2 -VASc: 0.62 (0.61–0.64), HAS-BLED: 0.62 (0.58–0.66)). Network meta-regression found no significant differences in predictive ability. CHA 2 DS 2 -VASc score had consistently high negative predictive value (≥94%) at one, three and five years of follow-up; conversely it showed the highest probability of being the best performing score (63% at one year, 60% at three years, 68% at five years). Conclusion In atrial fibrillation patients, contemporary clinical risk scores are associated with an increased risk of all-cause death. Use of these scores for death prediction in atrial fibrillation patients could be considered as part of holistic clinical assessment. The CHA 2 DS 2 -VASc score had consistently high negative predictive value during follow-up and the highest probability of being the best performing clinical score.
No takes yet. Share an insight, caveat, or question.
Proietti et al. (2018) conducted a systematic review in Atrial fibrillation (n=669,217). Clinical risk scores (CHADS2, CHA2DS2-VASc, HAS-BLED) was evaluated on Predictive ability for all-cause death at 5 years (c-index) (c-index 0.64 (CHADS2), 95% CI 0.63-0.65). Clinical risk scores showed modest predictive ability for 5-year all-cause mortality in atrial fibrillation, with c-indexes of 0.64 for CHADS2 and 0.62 for CHA2DS2-VASc.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: